Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04838444 · ClinicalTrials.gov registry record · Phase 3

Antibody Persistence And Long Term Safety Of A Chikungunya Virus Vaccine (VLA1553)

A Phase 3 study of Chikungunya Virus Infection, sponsored by Valneva Austria.

Active
Registry status
Phase 3
Development phase
363
Enrollment target
10
Study locations

NCT04838444 is a Phase 3 study of Chikungunya Virus Infection that is active but no longer recruiting, run by Valneva Austria. The registered enrollment target is 363 participants, roughly in line with the 367-participant average among 4 other Chikungunya Virus Infection trials with a reported enrollment target. The trial reports 10 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04838444, a Phase 3 study of Chikungunya Virus Infection, is active but no longer recruiting, sponsored by Valneva Austria.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
363 participants
Enrollment target
10
Study locations

Study Summary

In this open-label Phase 3b, single arm trial, persistence of antibodies and long term safety will be evaluated in up to 375 participants rolled over from trial VLA1553-301 (NCT number: NCT04546724).

Conditions Studied

Chikungunya Virus Infection

Interventions

  • BIOLOGICAL VLA1553

Study Locations (10)

Nebraska

  • Velocity Clinical Research - Grand Island
  • Velocity Clinical Research - Omaha

Arizona

  • Accelerated Enrollment Solutions (AES) - Phoenix

Florida

  • Velocity Clinical Research - Hallandale

Illinois

  • Accelerated Enrollment Solutions (AES) - Chicago

Kentucky

  • Alliance for Multispecialty Research (AMR) - Lexington

Tennessee

  • Alliance for Multispecialty Research (AMR) - Knoxville

Texas

  • Velocity Clinical Research - Austin

Utah

  • Velocity Clinical Research - West Jordan

Trial Details

FieldValue
Enrollment Target 363 participants
Start Date 2021-04-02
Est. Completion 2031-05
Phase Phase 3

Sponsor

Valneva Austria

11 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04838444

The ClinicalTrials.gov registry entry for NCT04838444 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 363 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 367-participant average among 4 other Chikungunya Virus Infection trials with a reported enrollment target. The listed sponsor is Valneva Austria, which has 11 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Chikungunya Virus Infection appearing as the primary indexed condition, and to 1 intervention - of which VLA1553 is the first listed.

NCT04838444 reports 10 study locations spanning 9 distinct geographic areas - top geographies include Nebraska, Arizona, Florida.

Frequently Asked Questions

What is clinical trial NCT04838444 about?

NCT04838444 is a clinical study titled "Antibody Persistence And Long Term Safety Of A Chikungunya Virus Vaccine (VLA1553)". In this open-label Phase 3b, single arm trial, persistence of antibodies and long term safety will be evaluated in up to 375 participants rolled over from trial VLA1553-301 (NCT number: NCT04546724).

What is the current status of trial NCT04838444?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 363 participants. The study started on 2021-04-02. Estimated completion is 2031-05.

What conditions does trial NCT04838444 study?

This clinical trial studies the following conditions: Chikungunya Virus Infection.

What interventions are being tested in trial NCT04838444?

The interventions under investigation include: VLA1553 (BIOLOGICAL).

Who is sponsoring clinical trial NCT04838444?

This trial is sponsored by Valneva Austria, which has 11 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04838444 being conducted?

This trial has 10 study locations across Arizona, Florida, Illinois, Kentucky, Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Chikungunya Virus Infection

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Chikungunya Virus Infection

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.